Company intelligence
Intensity Therapeutics, Inc.
A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.
About Intensity Therapeutics, Inc.
Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. Intensity is based in Westport, Connecticut. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.
Verified activity
Signals from Intensity Therapeutics, Inc.
5 published signals
Presence & Recognition
Intensity Therapeutics, Inc. will present its company on-demand beginning September 11 at 7:00 a.m. ET to provide investors with information about its lead investigational candidate INT230-6 and late-stage clinical development programs.
Reported by Intensity Therapeutics, Inc.
Presence & Recognition
Intensity Therapeutics, Inc. is heading to New York to participate in the H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference in New York from September 14 to 16 at the Lotte New York Palace Hotel.
Reported by Intensity Therapeutics, Inc.
Partnerships
Intensity Therapeutics, Inc. entered into a Collaborative Research and Development Agreement with the National Cancer Institute to study the efficacy, mechanism of action, and immune response associated with Intensity’s intratumoral approach.
Reported by Intensity Therapeutics, Inc.
Partnerships
Intensity Therapeutics, Inc. collaborated with Merck to evaluate INT230-6 in combination with KEYTRUDA in advanced solid malignancies.
Reported by Intensity Therapeutics, Inc.
Partnerships
Intensity Therapeutics, Inc. collaborated with Bristol Myers Squibb to evaluate INT230-6 in combination with Yervoy in patients with solid tumors.
Reported by Intensity Therapeutics, Inc.